Osaic Holdings
TVRD

Osaic Holdings’s Tvardi Therapeutics TVRD Stock Holding History

Osaic Holdings’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44 Buy
24
+22
+1,100% +$69 ﹤0.01% 7881
2026
Q1 		$6 Sell
2
-27
-93% -$106 ﹤0.01% 7758
2025
Q4 		$123 Hold
29
– – ﹤0.01% 7628
2025
Q3 		$1.02K Sell
29
-12
-29% -$342 ﹤0.01% 7342
2025
Q2 		$954 Sell
41
-3
-7% -$71 ﹤0.01% 7167
2025
Q1 		$672 Buy
44
+5
+13% +$75 ﹤0.01% 6925
2024
Q4 		$719 Sell
39
-224
-85% -$2.44K ﹤0.01% 6928
2024
Q3 		$2.93K Sell
263
-36
-12% -$422 ﹤0.01% 6454
2024
Q2 		$2.8K Sell
299
-49
-14% -$1.17K ﹤0.01% 6465
2024
Q1 		$11.4K Buy
348
+117
+51% +$3.03K ﹤0.01% 5676
2023
Q4 		$6.17K Sell
231
-798
-78% -$33K ﹤0.01% 6071
2023
Q3 		$62.2K Buy
1,029
+39
+4% +$3.66K ﹤0.01% 4833
2023
Q2 		$101K Buy
990
+8
+0.8% +$1.1K ﹤0.01% 4425
2023
Q1 		$174K Sell
982
-21
-2% -$7.03K ﹤0.01% 3982
2022
Q4 		$388K Buy
1,003
+853
+569% +$324K ﹤0.01% 3256
2022
Q3 		$52K Sell
150
-6
-4% -$2.17K ﹤0.01% 4881
2022
Q2 		$51K Sell
156
-21
-12% -$7.37K ﹤0.01% 4952
2022
Q1 		$1.71M Buy
177
+6
+4% +$2.46K ﹤0.01% 2071
2021
Q4 		$74K Buy
171
+1
+0.6% +$502 ﹤0.01% 4836
2021
Q3 		$94K Buy
170
+21
+14% +$10.5K ﹤0.01% 4585
2021
Q2 		$76K Sell
149
-56
-27% -$35.5K ﹤0.01% 4721
2021
Q1 		$160K Sell
205
-24
-10% -$16.4K ﹤0.01% 3950
2020
Q4 		$126K Sell
229
-11
-5% -$5.77K ﹤0.01% 3889
2020
Q3 		$110K Sell
240
-125
-34% -$72.6K ﹤0.01% 3746
2020
Q2 		$225K Sell
365
-72
-16% -$39.8K ﹤0.01% 3032
2020
Q1 		$207K Buy
+437
New +$237K ﹤0.01% 2838

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Osaic Holdings's TVRD Position: Q2 2026 in Review

Osaic Holdings increased its Tvardi Therapeutics (TVRD) stake by 1,100% in Q2 2026, buying an estimated $69 and bringing the position to 24 shares worth $44. The position accounts for ﹤0.01% of the portfolio, ranked #7881.

Osaic Holdings first reported a position in TVRD in Q1 2020 and has held it in 26 quarters since. The position peaked at $1.71M in Q1 2022. 57 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Osaic Holdings held 24 shares of Tvardi Therapeutics worth $44 as of Q2 2026.
  • Osaic Holdings bought 22 Tvardi Therapeutics shares in Q2 2026, an estimated $69.
  • Tvardi Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7881 holding.
  • Osaic Holdings first reported a position in Tvardi Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Tvardi Therapeutics position peaked at $1.71M in Q1 2022.
  • 57 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.